Victory Capital Management Inc. raised its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 6.7% during the fourth quarter, HoldingsChannel reports. The firm owned 19,923 shares of the medical research company’s stock after buying an additional 1,248 shares during the period. Victory Capital Management Inc.’s holdings in Thermo Fisher Scientific were worth $3,783,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also made changes to their positions in the business. Captrust Financial Advisors bought a new stake in shares of Thermo Fisher Scientific in the 2nd quarter valued at approximately $338,000. Courier Capital LLC bought a new stake in shares of Thermo Fisher Scientific in the 2nd quarter valued at approximately $203,000. Findlay Park Partners LLP increased its holdings in shares of Thermo Fisher Scientific by 11.1% in the 2nd quarter. Findlay Park Partners LLP now owns 2,257,151 shares of the medical research company’s stock valued at $393,805,000 after acquiring an additional 225,000 shares during the last quarter. Comerica Securities Inc. increased its holdings in shares of Thermo Fisher Scientific by 2.1% in the 2nd quarter. Comerica Securities Inc. now owns 5,587 shares of the medical research company’s stock valued at $976,000 after acquiring an additional 115 shares during the last quarter. Finally, BlackRock Inc. increased its holdings in shares of Thermo Fisher Scientific by 1.6% in the 2nd quarter. BlackRock Inc. now owns 23,355,469 shares of the medical research company’s stock valued at $4,074,828,000 after acquiring an additional 366,584 shares during the last quarter. 86.11% of the stock is currently owned by institutional investors.
Thermo Fisher Scientific Inc. (TMO) opened at $210.61 on Friday. The company has a market capitalization of $84,450.00, a price-to-earnings ratio of 34.53, a P/E/G ratio of 1.54 and a beta of 1.11. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.92 and a current ratio of 1.35. Thermo Fisher Scientific Inc. has a 52 week low of $151.74 and a 52 week high of $226.44.
Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, January 31st. The medical research company reported $2.79 EPS for the quarter, topping the Zacks’ consensus estimate of $2.66 by $0.13. The firm had revenue of $6.05 billion during the quarter, compared to the consensus estimate of $5.72 billion. Thermo Fisher Scientific had a return on equity of 16.01% and a net margin of 10.64%. The firm’s revenue was up 22.1% on a year-over-year basis. During the same period in the prior year, the business earned $2.41 EPS. analysts anticipate that Thermo Fisher Scientific Inc. will post 10.81 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Monday, April 16th. Investors of record on Thursday, March 15th will be paid a dividend of $0.17 per share. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.15. This represents a $0.68 dividend on an annualized basis and a yield of 0.32%. The ex-dividend date is Wednesday, March 14th. Thermo Fisher Scientific’s dividend payout ratio is presently 9.84%.
In related news, CEO Marc N. Casper sold 50,000 shares of the company’s stock in a transaction on Friday, December 15th. The stock was sold at an average price of $191.74, for a total transaction of $9,587,000.00. Following the completion of the transaction, the chief executive officer now directly owns 302,577 shares in the company, valued at approximately $58,016,113.98. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, SVP Gregory J. Herrema sold 33,327 shares of the company’s stock in a transaction on Friday, February 2nd. The stock was sold at an average price of $219.70, for a total value of $7,321,941.90. Following the transaction, the senior vice president now owns 60,471 shares of the company’s stock, valued at $13,285,478.70. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 94,327 shares of company stock valued at $19,260,542. 0.49% of the stock is owned by company insiders.
TMO has been the subject of a number of research analyst reports. Deutsche Bank set a $226.00 price target on Thermo Fisher Scientific and gave the company a “buy” rating in a report on Thursday, October 26th. Zacks Investment Research downgraded Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Monday, October 30th. Leerink Swann reiterated a “buy” rating on shares of Thermo Fisher Scientific in a report on Monday, October 30th. Evercore ISI initiated coverage on Thermo Fisher Scientific in a report on Wednesday, January 3rd. They issued an “outperform” rating and a $220.00 price target for the company. Finally, BTIG Research initiated coverage on Thermo Fisher Scientific in a report on Friday, January 5th. They issued a “buy” rating and a $230.00 price target for the company. Two equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $220.50.
Thermo Fisher Scientific Profile
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.